An open-label, single-arm, prospective, multi-center, tandem two-stage designed phase II study to evaluate the efficacy of fulvestrant in women with recurrent/metastatic estrogen receptor-positive gynecological malignancies (FUCHSia study).
Rita TrozziSandra TuyaertsDaniela AnnibaliAlejandro Herreros PomaresLotte BoogPeter Van DamKarin LeunenChristophe DerooseHans TrumFrédéric AmantPublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2024)
Fulvestrant may control tumor growth in recurrent/metastatic estrogen receptor-positive low-grade gynecological malignancies of specific histology. Further studies are needed to confirm these results.